1. Academic Validation
  2. Discovery and characterization of 2-(cyclopropanesulfonamido)-N-(2-ethoxyphenyl)benzamide, ML382: a potent and selective positive allosteric modulator of MrgX1

Discovery and characterization of 2-(cyclopropanesulfonamido)-N-(2-ethoxyphenyl)benzamide, ML382: a potent and selective positive allosteric modulator of MrgX1

  • ChemMedChem. 2015 Jan;10(1):57-61. doi: 10.1002/cmdc.201402277.
Wandong Wen 1 Yan Wang Zhe Li Pang-Yen Tseng Owen B McManus Meng Wu Min Li Craig W Lindsley Xinzhong Dong Corey R Hopkins
Affiliations

Affiliation

  • 1 Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt Specialized Chemistry Center (MLPCN), Vanderbilt University Medical Center, Nashville, TN 37232-6600 (USA).
Abstract

Previous studies have shown that the activation of mouse MrgC11, a G-protein-coupled receptor, by its peptide ligand BAM8-22 can inhibit chronic pain. A large-scale screen has been carried out to isolate small-molecule allosteric agonists of MrgX1, the human homologue of MrgC11. The goal of this study is to improve the efficacy and potency of positive allosteric modulators (PAMs) with therapeutic implications in combating chronic pain. Herein we report an iterative parallel synthesis effort and a structure-activity relationship study of a series of arylsulfonamides which led to the discovery of the first PAM of MrgX1, ML382.

Keywords

ML382; MLPCN; MrgX1; chronic pain; molecular probes; positive allosteric modulators.

Figures
Products